ASCO20: How does early treatment influence the sequence of the following treatment if the disease progresses?

Eric J. Small | ASCO20 Virtual | Juni 9, 2020

Speaker: Eric J. Small

In this MEDtalk Eric J. Small, MD and principal investigator of the SPARTAN study, explains the clinical benefits from early treatment of patients with nonmetastatic castration-resistant prostate cancer